CEO Anevski now owns $17 million worth of Progyny.
Progyny's stock popped roughly 8% the day of the announcement.
Peter Anevski, Chief Executive Officer of Progyny (NASDAQ:PGNY), purchased 79,500 shares in the open market on Nov. 13, 2025, as disclosed in a SEC Form 4 filing.
| Metric | Value |
|---|---|
| Shares traded | 79,500 |
| Transaction value | ~$1.9 million |
| Post-transaction shares | 680,251 |
| Post-transaction value (direct ownership) | ~$16.6 million |
Transaction value based on SEC Form 4 weighted average purchase price ($24.29); post-transaction value based on Nov. 13, 2025, market close price.
| Metric | Value |
|---|---|
| Revenue (TTM) | $1,268.69 million |
| Net income (TTM) | $56.57 million |
| Price (as of market close 12/2/25) | $24.95 |
| 1-year price change | 60% |
Note: 1-year performance calculated using Nov. 13th, 2025, as the reference date.
Progyny:
Progyny operates at scale within the healthcare information services sector, focusing on fertility and family-building benefit management for employers.
The company leverages a differentiated plan design and a curated provider network to deliver value-added services and outcomes.
Its integrated approach and specialized offerings position it as a leading provider in the employer-sponsored fertility benefits market.
Chief Executive Officer Peter Anevski's purchase of Progyny stock is undoubtedly a noteworthy event for investors.
Anevski purchased the shares using his own cash to offset tax withholding obligations, so in this sense, they believe that the shares are a value at today's price. If not, Anevski could have just let the company withhold shares to cover their withholding tax.
So while this wasn't a "pure bet" on Progyny stock, it is a nuanced buy signal from the leader of the industry-leading fertility benefits company.
Following a quarter where Progyny reported 9% sales growth, continued to see its cash flows balloon, and saw near-100% customer retention, I'd argue it's pretty clear why Anevski was happy to buy shares with his own money.
From a longer-term Foolish perspective, there's a lot to like about the fertility benefits specialist as global fertility rates unfortunately continue to decline, making the upstart company's products a clear benefit to society.
Still trading at just 12 times free cash flow and 14 times forward earnings, Progyny looks discounted and remains one of my favorite stocks to buy, especially with some of the best Net Promoter Scores in the healthcare industry.
Form 4: A required SEC filing disclosing insider transactions in a company's securities by officers, directors, or major shareholders.
Open market purchase: Buying shares directly on a public exchange, rather than through private transactions or option exercises.
Direct ownership: Shares held personally by an individual, not through trusts, funds, or indirect means.
Outstanding shares: The total number of a company's shares currently held by all shareholders, including insiders and the public.
Weighted average purchase price: The average price paid per share, adjusted for the number of shares bought at each price.
Total return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested.
Trailing twelve months (TTM): The 12 months ending with the most recent quarterly report.
Concierge support: Personalized assistance provided to clients, often to help navigate complex services or benefits.
Provider network: A group of professionals or organizations contracted to deliver specific services to clients or members.
Benefit management: The administration and coordination of employee benefits, such as healthcare or family-building services, for organizations.
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,012%* — a market-crushing outperformance compared to 193% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of December 1, 2025
Josh Kohn-Lindquist has positions in Progyny. The Motley Fool has positions in and recommends Progyny. The Motley Fool has a disclosure policy.